Skip to main content
Premium Trial:

Request an Annual Quote

Karo Bio Selects Elsevier's Reaxys to Support Medicinal Chemistry Projects


Elsevier said this week that Karo Bio has licensed its Reaxys suite to help its chemists identify and prioritize viable drug compounds for further research and development.

Specifically, Karo's chemists are using Elsevier's Reaxys and Reaxys Medicinal Chemistry solutions. These tools give researchers access to biological and chemistry data from periodicals, peer-reviewed journal articles, and patents.

The financial details of the agreement were not disclosed.

Elsevier's Reaxys portfolio is one of several products for drug discovery and development offered by the company's life science solutions business. Other tools in the unit include ScienceDirect, Scopus, TargetInsights, Pathway Studio, PharmaPendium, QUOSA, and Embase.